Phase 1 Quality Clinical Trials
9 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–9 of 9 trials
Recruiting
Phase 1Phase 2
Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease
Quality of LifeDepression, AnxietyStress Reaction+1 more
Children's Hospital Los Angeles66 enrolled1 locationNCT05685368
Recruiting
Phase 1
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
Pleural CarcinomatosisQuality of LifeChemotherapy Effect+4 more
Odense University Hospital20 enrolled1 locationNCT06421610
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of N-acetyl-5-methoxytryptamine prolonged release tablet against the innovator N-acetyl-5-methoxytryptamine prolonged release tablet conducted under fed conditions in healthy male and female volunteers.
N-acetyl-5-methoxytryptamine is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12622000966796
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of N-acetyl-5-methoxytryptamine prolonged release tablet against the innovator N-acetyl-5-methoxytryptamine prolonged release tablet conducted under fasting conditions and at steady state in healthy male and female volunteers.
N-acetyl-5-methoxytryptamine is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12622000957796
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of N-acetyl-5-methoxytryptamine prolonged release tablet against the innovator N-acetyl-5-methoxytryptamine prolonged release tablet conducted under fasting conditions in healthy male and female volunteers.
N-acetyl-5-methoxytryptamine is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12622000956707
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet against the innovator N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet conducted under fed conditions in healthy male and female volunteers.
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12622000126718
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet against the innovator N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet conducted under fasting conditions and at steady state in healthy male and female volunteers.
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12622000109707
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet against the innovator N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet conducted under fasting conditions in healthy male and female volunteers.
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12622000108718
Not Yet Recruiting
Phase 1
Influence of Omega 3 fatty acids on osmosensation and thirst signaling
Improving thirst sensation by supplementation of Omega 3 fatty acidsFluid intakeImproving dehydration in elderly by supplementation of Omega 3 fatty acids+1 more
Victoria University, Melbourne40 enrolled1 locationACTRN12610000398000